Purpose We previously showed that carfilzomib (CFZ) has potent anti-proliferative and cytotoxic activity in a broad range of lung cancer cell lines. Here we investigate possible mechanisms of CFZ acquired resistance in lung cancer cell lines. Methods CFZ-resistant non-small cell lung cancer (NSCLC) cell lines were developed by exposing A549 and H520 cells to stepwise increasing concentrations of CFZ. Resistance to CFZ and cross-resistance to bortezomib and other chemotherapy drugs was measured using the MTT assay. Cytotoxicity to CFZ was determined using a CytoTox assay. Western blot was used to measure apoptosis, autophagy, and drug efflux transporter-related proteins. Quantitative targeted whole transcriptome sequencing and quantitative RT-PCR was used to measure gene expression. Flow cytometry was used to analyze intracellular accumulation of doxorubicin. Results The CFZ IC 50 value of the resistant cells increased versus parental lines (2.5-fold for A549, 122-fold for H520). Resistant lines showed reduced expression of apoptosis and autophagy markers and reduced death versus parental lines following CFZ treatment. Both resistant lines exhibited higher P-glycoprotein (Pgp) gene (TempO-Seq® analysis, increased 1.2-fold in A549, > 9000-fold in H520) and protein expression levels versus parental lines. TempO-Seq® analysis indicated other drug resistance pathways were upregulated. The resistant cell lines demonstrated less accumulation of intracellular doxorubicin, and were cross-resistant to other Pgp client drugs: bortezomib, doxorubicin, and paclitaxel, but not cisplatin. Conclusions Upregulation of Pgp appears to be an important, but not the only, mechanism of CFZ resistance in NSCLC cell lines.
Introduction
Intracellular proteins with short half-lives and those that are damaged or improperly folded are degraded via the ubiquitin-proteasome system. Cancer cells generally have higher levels of proteasome activity than normal cells due to their higher proliferative rate and are, therefore, more susceptible to cell death upon proteasome inhibition. Pharmacological inhibition of the proteasome has proven to be an efficacious treatment for multiple myeloma (MM) (Hideshima et al. 2001 ) and mantle cell lymphoma (O'Connor et al. 2005) using the first-generation proteasome inhibitor, bortezomib (BTZ). Second-generation proteasome inhibitors have been investigated both pre-clinically and clinically including carfilzomib (CFZ) (Baker et al. 2014; Papadopoulos et al. 2013; Siegel et al. 2012; Vij et al. 2012) , which is approved Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s0043 2-018-2662-0) contains supplementary material, which is available to authorized users.
by the Food and Drug Administration for the treatment of MM.
Proteasome inhibition as a therapeutic strategy for solid tumors has yielded less favorable clinical outcomes than for hematologic malignancies, implying that protein degradation may be a less important target in solid tumors. Solid tumors may also have different primary and acquired resistance mechanisms than hematologic malignancies. BTZ yielded disappointing results in clinical trials of solid tumors (Huang et al. 2014) . Fewer clinical studies of CFZ in solid tumors have been reported; however, one phase I/II study reported limited antitumor activity across a broad range of solid tumors (Papadopoulos et al. 2013) . Further clinical studies with CFZ in solid tumors and neuroendocrine malignancies are ongoing (see clinicaltrials.gov).
Patients acquire resistance to proteasome therapy (Rumpold et al. 2007; Schmidmaier et al. 2007) , and the acquisition of such resistance may account for the limited efficacy of proteasome inhibitors in treating solid tumors. Understanding the mechanism of acquired resistance will be important to interpreting and guiding the clinical experience with CFZ in solid tumors.
One shared resistance mechanism across chemotherapeutic agents is an increased expression of drug efflux pumps that prevents or reduces intracellular accumulation of toxins and xenobiotics. The best-characterized transporters that have been implicated as major contributors to multidrug resistance in cancer are P-glycoprotein (Pgp), also known as multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), or ABCB1 (Eckford and Sharom 2009) . A study utilizing multiple cell lines with various multidrug-resistant transporters indicated that only Pgp was able to pump epoxyketone-based PIs including CFZ out of the cells and facilitate resistance (Verbrugge et al. 2012) . Another study using human lung and colon adenocarcinoma cell lines also determined that Pgp upregulation played a major role in acquired resistance to CFZ (Ao et al. 2012 ). However, while these studies in cell lines suggested Pgp-mediated acquired CFZ resistance, clinically, BTZ and CFZ do not always have the same mechanism of resistance, with patients who were refractory to BTZ often still being responsive to CFZ treatment (Jain et al. 2011) .
Besides Pgp and other efflux pump mechanisms, it has been reported that amplification or mutation of target proteasome subunits (Lu et al. 2008; Oerlemans et al. 2008) , suppression of protein biosynthesis (Ruckrich et al. 2009 ), changes to the endoplasmic reticulum stress responses (Zhang et al. 2010) , or formation of stress granules (Gareau et al. 2011) , are other mechanisms of resistance to BTZ.
To investigate acquired mechanisms of resistance to CFZ in non-small cell lung cancer (NSCLC), we generated two CFZ-resistant cell lines. Upregulation of Pgp was observed in both CFZ-resistant cell lines. These results support prior observations by others, and highlight the need to consider this resistance pathway when designing clinical trials using CFZ and other proteasome inhibitors in solid tumors, including NSCLC.
Materials and methods

Reagents and antibodies
CFZ, supplied by Onyx Pharmaceuticals, Inc., an Amgen subsidiary (South San Francisco, CA), was dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) at a concentration of 10 mM with stock aliquots stored at − 20 °C. BTZ, obtained from Cell Signaling Technology (La Jolla, CA), was also prepared in DMSO and stored at − 20 °C in 10 mM aliquots. Paclitaxel (Sigma-Aldrich) was dissolved in DMSO and stored in 7 mM aliquots at − 20 °C. Doxorubicin (Sigma-Aldrich) was dissolved in saline at 2 mg/ml (3.68 mM) and stored in aliquots at − 20 °C. Paclitaxel (Sigma-Aldrich) was prepared in DMSO at 7 mM and stored as aliquots at − 20 °C. Cisplatin (Sigma-Aldrich) was dissolved in saline and stored at − 20 °C as 5.5 mM aliquots. Antibodies against cleaved caspase-3 (catalog #9664) and Pgp (MDR1/ABCB1) (catalog #13342) were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against LC3B (catalog # L7543) were obtained from SigmaAldrich. Alpha-tubulin antibodies (catalog #MAB1864-I) were purchased from Calbiochem (La Jolla, CA). Secondary antibodies, HRP-conjugated goat anti-rabbit (catalog # 111-035-003) and HRP-conjugated goat anti-mouse (catalog # 115-035-003), were purchased from Jackson ImmunoResearch (West Grove, PA).
Cell lines
Two NSCLC cell lines, A549 and NCI-H520, were obtained from the American Tissue and Cell Collection (ATCC) (Manassas, VA). The A549 are alveolar basal epithelial adenocarcinoma cells that have mutated KRAS and functional EGFR. The H520 are squamous cell lung carcinoma cells that have considerably reduced p53 expression. A549-resistant cells (A549-R) and H520-resistant cells (H520-R) were created from the A549 and H520 parent cells through exposure to stepwise increasing doses of CFZ. Fresh CFZ-dosed media was applied every 2 days over several months. All cells were cultured in RPMI 1640 (Cellgro) with 10% fetal bovine serum (FBS; Seradigm, USA), 1 mM sodium pyruvate, and 1 × MEM non-essential amino acid solution. The resistant cell lines were maintained with exposure to CFZ (250 nM for A549-R and 500 nM for H520-R). All cells were grown in 5% CO 2 at 37 °C in a humidified tissue culture incubator. Cells were routinely tested for mycoplasma contamination using a MycoAlert mycoplasma detection kit (Lonza, Rockland, ME) and were found to be negative. To verify parent cell line authenticity, genomic DNA was extracted (Sigma GIN70-KT), diluted appropriately in TE buffer, and submitted to the University of Arizona Genomics Core (Human Origins Gentoyping Lab) for analysis. Autosomal STR typing was conducted across the 13 core STRs in CODIS and referenced against allelic peaks in cell lines of previously confirmed genotype. The cell lines were verified as authentic. Cells (5 × 10 3 ) were seeded in 96-well plates and incubated overnight. Cultures were exposed to various concentrations of drug for a 48-h treatment interval. Proliferation of cells was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. MTT dye (2 mg/ml) was added to the adherent cell culture and incubated for an additional 4 h at 37 °C. After removal of medium, the resulting formazan crystals were dissolved in DMSO for 5 min by shaking and the plates were then read in a spectrophotometer at 540 nm. Dose-response curves were created using GraphPad Prism version 5.01 (GraphPad Software Inc, La Jolla, CA). IC 50 values were calculated using CalcuSyn (Biosoft, Great Shelford, Cambridge, UK).
Proliferation assay
Cytotoxicity assay
Cell cytotoxicity based on detection of intracellular protease activity (dead-cell protease) was performed using the CytoTox-Glo assay (Promega). Cells (5 × 10 3 ) were seeded in 96-well white-walled plates and incubated overnight. Multiples of predetermined 48 h IC 50 doses of CFZ were applied to the cells. Following a further 48-h incubation, the CytoTox-Glo kit was used according to the manufacturer's instructions to determine the percentage of dead cells relative to the total amount of cells. Briefly, the cytotoxicity reagent was added to each well and after 15 min of incubation, luminescence was measured by a Beekman Coulter Multimode DTX880 microplate reader. A reagent containing digitonin was then added to lyse any remaining viable cells. After another 15-min incubation, a second luminescence measurement was taken. The percentage of dead cells was calculated by dividing the first luminescence reading by the second after subtraction of the background signal from media only wells. Values are presented as a fold change compared to the vehicle-treated control.
Western blot analysis
After various time points, the cells were rinsed with cold phosphate-buffered saline (PBS) and harvested in a buffer containing 50 mM Tris-HCl, 150 mM NaCl, 0.1% Triton X-100, 2 mM EDTA supplemented with Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL). The cell lysate was sonicated and centrifuged at 10,000×g for 8 min at 4 °C. Protein concentration of the resulting supernatant was determined using a 660 nm protein assay kit (Thermo Scientific). Twenty micrograms of total cell lysate was boiled for 5 min and resolved in a 10% acrylamide/bisacrylamide gel by electrophoresis at 125 V for 105 min. Proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA). Membranes were blocked with 5% milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 30 min before overnight incubation at 4 °C with various primary antibodies, typically at a 1:1000 dilution. Blots were rinsed with TBST and incubated for 2 h at room temperature with secondary antibody at a 1:15,000 dilution. Reactive bands were visualized by exposure to film using Pierce Supersignal West Pico HRP Detection Reagent (Thermo Fisher Scientific, Rockford IL). Blots were stripped with OneMinute Plus Western Blot Stripping Buffer (GM Biosciences, Frederick, MD) and then re-probed for loading control using alpha-tubulin.
Differential gene expression analysis
The gene expression patterns of the cell lines were analyzed and compared using TempO-Seq® human whole transcriptome reagent kits (BioSpyder Technologies, Inc., Carlsbad, CA). The Whole Transcriptome TempO-Seq assay measures 18,886 genes, the entire human transcriptome (Yeakley et al. 2017) . The kits consist of a 2X lysis buffer for making cell lysates, a detector oligo (DO) cocktail for measurement of the whole transcriptome, annealing, nuclease and ligation reagents, amplification reagents for preparing libraries for sequencing on Illumina instruments, and a custom index 1 sequencing primer. Additional reagents were obtained from VWR or Sigma-Aldrich. The TempO-Seq assay was performed according to the manufacturer's instructions, using a 96-well PCR plate in a BioRad C1000/CFX96 real-time qPCR instrument. Briefly, cells were washed once with 1X PBS before lysis in 1X lysis buffer with 10 min of incubation at room temperature. The resulting cell lysate was either used that day or stored at − 80 °C until analysis. DO cocktail (2 µL) was added to 2 µL of the lysate, heated to 70 °C and then reduced to 45 °C over 50 min to permit the DOs to hybridize to their respective RNA targets. Nuclease mix (24 µL) was added with incubation at 37 °C for 90 min, followed by the addition of ligase (24 µL) mix and an additional incubation of 60 min. The mix was then incubated for 15 min at 80 °C. This product (15 µL) was then transferred into a second PCR plate pre-loaded with 10 µL of PCR amplification mix containing the PCR primers (designed to add a different sample-specific index sequence to each sample), a green fluorescent dsDNA dye, and polymerase. Six cycles were carried out at an annealing temperature of 54 °C followed by 19 cycles at 66 °C, with the yield monitored at each cycle using the dye. The amplified samples were then pooled together and the sequencing library was purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel cat# 740609.50) with no changes to kit formulations. Sequencing was performed by a service provider using the Illumina NextSeq instrument. In addition to the cell samples, a no-sample-input control was also processed through the TempO-Seq and PCR amplification assay steps to measure background. After sample demultiplexing using Illumina sequencer default settings, FASTQ files were aligned to the probe sequences using Bowtie, allowing for up to 2 mismatches in the 50 bp target sequence, using the data TempO-SeqR analysis software provided with the assay kits. Data normalization was carried out using a package in the TempO-SeqR analysis software, and differential expression analysis was carried out using the DESeq2 package in R (Love et al. 2014 ).
Q-RT-PCR
Total cellular RNA was isolated using the RNeasy Plus Mini kit (Qiagen, Valencia, CA) and quantified with a spectrophotometer. cDNA was then generated from 0.5 ug of DNasefree RNA using the qScript cDNA synthesis kit (Quanta BioSciences, Gaithersburg, MD) following the manufacturer's instructions. Reverse transcription (RT) was performed using a GeneAmp 7300 sequence detection system (PE Biosystems, Foster City, CA). Amplification reactions were run in a reaction volume of 20 µL using the Applied Biosystems TaqMan Universal PCR Mastermix (Applied Biosystems, Branchburg, NJ). PCR primers and TaqMan probe for PGP were synthesized and pre-optimized by Applied Biosystems (Assays on Demand, catalog #4351372) (Foster City, CA). Each reaction contained 1 × PCR Mastermix, 900 nmol of each primer, and 250 nmol of the Fam probe. Reverse transcription was performed at 48 °C for 30 min, samples were incubated for 10 min at 95 °C and then amplified over 40 cycles for 15 s at 95 °C followed by 1 min at 60 °C. Values were normalized to human large ribosomal protein (RPLPO) message using and quantitated using the delta CT method as described by PerkinElmer. The RPLPO PCR primers and TaqMan probe were synthesized and pre-optimized by Applied Biosystems (Assays on Demand, catalog #4331182) (Foster City, CA).
Flow cytometry
Cells were seeded in 100-mm plates and incubated overnight. Cells were treated with media only or treated with media containing 10 µM doxorubicin for 1 h. The adherent cells were collected and rinsed with 2X PBS. The cells were analyzed by flow cytometry (FACSCanto II, BD Biosciences, San Jose, CA) with excitation at 488 nm and emission at 585 nm. Data analysis was performed using FlowJo software (Treestar Inc., Ashland, OR).
Results
Prolonged incremental drug exposure renders cells that are resistant to CFZ
The A549-R and H520-R cells were created as described in "Materials and methods". To evaluate these cells for CFZ sensitivity, the MTT assay was performed on the A549 and H520 parent and resistant cell lines. Cells were grown under selection pressure in the above-indicated amounts of carfilzomib until 24 h prior to seeding cells for MTT assays. Results from one representative experiment (n = 6) are shown in Fig. 1 . For both cell lines, the 48-h dose-response curves show that the resistant cell line variant is less sensitive to CFZ than its respective parent cell line. The CFZ IC 50 values were calculated from the dose-response curves and are compared in Table 1 . The A549-R cells showed approximately a 2.5-fold increase in CFZ IC 50 value over its parent (from 127 to 311 nM), while the H520-R cells showed more than a 100-fold increase in the CFZ IC 50 value over its parent (from 15 to 1840 nM).
Resistant cells have reduced cell death, cleaved caspase-3 and autophagy in response to CFZ treatment
The MTT assay results, based on mitochondrial activity, reflect changes related to both cytotoxicity and/or cell proliferation. To further investigate cytotoxicity, cell death was evaluated using the Promega CytoTox-Glo cytotoxicity assay. The release of "dead-cell protease activity" was initially measured as a result of CFZ treatment. The remaining viable cells were then lysed with digitonin and a second dead-cell protease activity measurement was obtained, reflecting total cells. The percentage of dead cells in each treatment group was obtained by dividing the first measurement by the second measurement and the values were then normalized to the untreated samples. Figure 2a shows that the rate of increase in the percent of dead cells with increasing CFZ dosage is lowered in the A549-R cells versus the A549 parent cells. While the H520 parent cells show an increase in the percent of dead cells with increasing CFZ treatment, the H520-R rate is less with no increase in dead cells since they remain completely resistant to CFZ at the doses used. Next, we examined the A549 and H520 parent and resistant cell lines for markers of apoptosis and autophagy using Western blot analysis. Levels of cleaved caspase-3, a marker of apoptosis, and LC3B-II, a marker of autophagy, were found to be lower for the same dose of CFZ in the resistant cells as compared to their parent (Fig. 2b) .
Pgp is upregulated in the CFZ-resistant cells
TempO-Seq analysis was performed to examine differentially expressed genes in the parent and CFZ-resistant cell lines. The ABCB1 gene, which encodes Pgp, was found to have a modest but significant increase in expression in A549-R cells compared to its parent (43 counts in A549 versus 51 counts in A549-R, a 1.2-fold change). There was a much more dramatic increase in ABCB1 expression in the H520-R cells compared to its parent (0.7 counts in H520 versus 6,267 counts in H520-R, a 1 > 9,000-fold change).
Refer to Supplemental Table 1 for data on ABCB1 and other select genes measured by TempO-SEq. To independently validate these results and further investigate Pgp as a pertinent mechanism of resistance to CFZ, quantitative RT-PCR and Western blot analyses were performed on the untreated parental and CFZ-resistant cell lines. PCR analysis demonstrated that Pgp transcripts are approximately twofold higher in the A549-R cells versus the parent A549 cells and approximately 11-fold higher in the H520-R cells versus the parent H520 cells (Fig. 3a) , consistent with the TempO-Seq data. Additionally, Western blot analysis showed a similar trend with Pgp protein levels substantially higher in the A549-R cells versus the parent A549 cells, and exceedingly higher in the H520-R cells versus the H520 parent cells (Fig. 3b) .
To confirm gene and protein expression related to functional activity, flow cytometry was performed to analyze the uptake of doxorubicin, a known client of Pgp. Following a 1-h exposure to doxorubicin, the A549 and H520 parent and resistant cells were washed and analyzed. Doxorubicin autofluorescent intensity was measured to determine the amount of uptake into the cells. Consistent with the Pgp message and protein results, Fig. 3c shows slightly less doxorubicin uptake in the A549-R cells versus the A549 parent cells and substantially less uptake of doxorubicin uptake in the H520-R cells versus the H520 parent cells.
Other upregulated pathways identified in CFZ-resistant cells
Having the whole transcriptome gene expression data from the TempO-Seq assay permitted us to look more broadly at mechanisms of drug resistance, in addition to Pgp, that were induced by the CFZ-conditioning treatment. The gene expression data identified other putative mechanisms for drug resistance that deserve future exploration (Supplemental Table 1): 1. SLC6A15, the neutral amino acid transporter, increased 49-fold in H520-R and 41-fold in A549-R. 2. ABCC2, a transporter of organic anions that may include cisplatin, increased 21-fold in H520-R. 3. The metabolism enzyme gene CYP2J2, significantly increased (≥ 117-fold) in A549-R, but significantly decreased (90%) in H520-R. 4. CYP4F11, a metabolism enzyme induced in both A549-R and H520-R cells.
To help confirm the relevance of the TempO-Seq gene expression observations, we focused on the change in KDM6A expression, a histone demethylase, which increased in the H520-R cells relative to their parent, but was not increased in A549-R cells. We exposed the cell lines to the single agent and combination treatments of CFZ and suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor that increases histone acylation and has anti-growth activity against NSCLC cells (Komatsu et al. 2006) . We have previously published evidence that combination treatment of CFZ plus SAHA was more efficacious that CFZ alone (Hanke et al. 2016 ). Since KDM6A is a histone demethylase, and SAHA is an inhibitor of histone deacetylases, the expectation is that SAHA would cause greater apoptosis and caspase-3 cleavage in the H520-R cells, where KDM6A was upregulated, than in A549-R cells, where KDM6A was not upregulated. Cleaved caspase-3 following treatment with CFZ, SAHA or the combination is shown in Supplemental  Fig. 1 . Consistent with increased KDM6A in H520-R cells but not A549-R, there was a greater effect of SAHA (greater caspase-3 cleavage indicative of greater SAHA-mediated apoptosis) in H520-R cells than A549-R cells compared to their parent. Interestingly, although co-treatment with CFZ + SAHA caused much greater cleavage of caspase-3 in A549-R cells than SAHA alone, the combined treatment was only effective in H520 cells, not the H520-R cells. This suggests that even though KDM6A increases the sensitivity of H520-R cells to SAHA, the much-reduced sensitivity to CFZ results in the combination therapy being less effective.
Sensitivity of CFZ-resistant cell lines to other chemotherapy drugs
To examine how the development of resistance to CFZ may affect sensitivity to other drugs that are known Pgp clients, MTT assays were performed on the cell lines following treatment with BTZ and other common cancer chemotherapies while cisplatin, which is not a Pgp client, was used as a control. The results from one representative experiment (n = 6) are shown in Fig. 4 . The CFZ-resistant cells showed cross-resistance to the first-generation proteasome inhibitor BTZ, a substrate of Pgp. The CFZ-resistant cells also showed cross-resistance to two other agents whose efflux is mediated by Pgp, doxorubicin and paclitaxel. However, the CFZ-resistant cells became mildly sensitized to cisplatin which is not a substrate of the Pgp efflux pump. Table 2 provides a comparison of the IC 50 values between the CFZ-resistant and parent cell lines when treated with these chemotherapy agents. The fold change in IC 50 of the CFZresistant cells compared to parent is 2.4-fold and 19.5-fold for the first-generation proteasome inhibitor BTZ in A549 and H520 cells, respectively. This is consistent with the greater resistance of the H520-R cells to CFZ than that of the A549-R cells, and consistent with the larger increase of Pgp expression over its parent found in the H520-R cells versus that of the A549-R cells. Cross-resistance of doxorubicin and paclitaxel, two non-proteasome-targeted drugs whose efflux are mediated by Pgp, exhibited a similar 2.4-and 5.1-fold increase in IC 50 values, respectively, in A549-R cells, and consistently greater 6.8-and 517-fold change in IC 50 values, respectively, in H520-R cells. TempO-Seq analysis showed a more than 150-fold increase in expression of the TUBA4A gene (whose protein product is the target of paclitaxel) in the H520-R cells versus its parent (Supplemental Table 1 ). This directly correlates to the 517-fold increase in the paclitaxel IC 50 value found in the H520-R cells versus its parent (Table 2 ). In contrast to the agents that are substrates of Pgp, sensitivity to cisplatin, whose efflux from cells is not mediated by Pgp, increased, with a 0.44-fold change in A549-R and a 0.41-fold change in H520-R cells.
Discussion
Although the use of first-or second-generation proteasome inhibitors in multiple myeloma and mantle cell lymphoma is frequently associated with initial robust clinical response, patients frequently become refractory or resistant to proteasome inhibitor-based therapy (Mitra et al. 2014) . Historically, solid tumors have demonstrated disappointing sensitivity to proteasome inhibitor therapy, in spite of inherent sensitivity to proteasome inhibitor treatment in in vitro solid tumor models. Multiple mechanisms of both inherent and acquired resistance to proteasome inhibition have been reported including upregulation of Pgp (Grogan et al. 1993) , enhanced protection from oxidative stress via activation of nuclear factor kB (NFkB) and nuclear respiratory factor 2 (Nrf-2) transcription factors (Rushworth et al. 2012) , inhibition of apoptotic pathways (Chauhan et al. 2007) , and activation of pro-survival signaling pathways (Frassanito et al. 2016 ).
The results of our experiments demonstrate that NSCLC cell lines induce resistance to CFZ through chronic exposure. The development of resistance to CFZ is reflected by an increase in the dose-response IC 50 (Fig. 1) , a decrease in cytotoxicity (Fig. 2a) , and reduced markers of apoptosis and autophagy (Fig. 2b) . We observed that the resistant cell populations express higher levels of Pgp compared to their respective parent. Notably, A549 parent cells have higher basal levels of Pgp versus H520 parent cells and are also more inherently resistant to CFZ (A549 CFZ IC50 of 125 nM versus H520 CFZ IC50 of 15 nM) (Baker et al. 2014) . While the A549-R cells show only a small fold increase in CFZ resistance over A549 parent cells, H520-R cells show a much larger increase in acquired resistance over H520 cells. Therefore, cells that are initially highly sensitive to CFZ because of low Pgp may have the potential to become highly resistant once Pgp upregulation occurs. In addition to Pgp, gene profiling has identified additional adaptive changes in the CFZ-resistant cells compared to parental cells (Mitra et al. 2017; Riz et al. 2015 Riz et al. , 2016 Zheng et al. 2017) .
Given the prevalence of Pgp-mediated chemotherapy resistance in NSCLC tumors, there is an urgent need for improved biomarkers that can be applied serially to predict and monitor biologics and chemotherapy sensitivity and resistance. Importantly, we showed that gene expression of Pgp measured by the whole transcriptome RNA sequencing platform TempO-Seq correlates with protein and functional expression. TempO-Seq can be extended to single cell analysis and, therefore, has the potential to be applied directly to circulating tumor cells to characterize drug-resistant phenotypes using serial liquid biopsies. Other high-throughput gene profiling methods have been applied to CTCs successfully (Park et al. 2016) . A small series of case studies applying serial monitoring of CTC gene expression profiles have supported the potential use of CTCs to monitor therapeutic efficacy and to identify biomarkers of drug resistance (Bielcikova et al. 2017) . These findings provide insights into the complex mechanisms of acquired CFZ drug resistance and demonstrate how cross-therapy resistance can be detected by leveraging gene expression profiling.
